On January 7, 2026 Artios Pharma Limited ("Artios"), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ("DDR") in cancer, reported that it will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco from January 12 to 15, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mike Andriole, Artios’ Chief Executive Officer, will highlight the company’s strategic priorities for its two differentiated, potential first-in-class clinical programs in cancers with high unmet need. The company’s ATR inhibitor, alnodesertib, selects for ATM-deficient patients whose tumors harbor high degrees of DNA replication stress where the program has generated responses across eight different tumor types in early clinical development. It is currently being evaluated in two Phase 2 expansion cohorts in colorectal and pancreatic cancers. The company is also initiating a randomized Phase 2 study of its potentially first-in-class DNA polymerase Theta (Polθ) inhibitor, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor.
The presentation will take place on Thursday, January 15, at 07:30 am PST (10:30 am EST / 03:30 pm UTC) in the Elizabethan B room (2nd floor) at The Westin St. Francis, 335 Powell Street, San Francisco.
(Press release, Artios Pharma, JAN 7, 2026, View Source [SID1234661795])